NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
Scotland says no to Daiichi Sankyo’s cholesterol drug NilemdoThe Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, Share XScotland says no to Daiichi Sankyo’s cholesterol drug Nilemdohttps://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/
